Results 201 to 210 of about 788,607 (367)

The 5 most frequently asked questions about factor Xa inhibitors. [PDF]

Hematology Am Soc Hematol Educ Program, 2022
Wang TF, Carrier M.
europepmc   +1 more source

tPA, but not uPA, Significantly Affects Antithrombotic Therapy by a Glycoprotein IIb/IIIa Antagonist, but not by a Factor Xa Inhibitor

, 2000
Motoi Nishida, Hiroyuki Matsuno, Osamu Kozawa, Shigeru Ueshima, Osamu Matsuo, D Collen, Toshihiko Uematsu   +6 more
openalex   +1 more source

Efficacy and Safety of Direct Oral Anti‐Coagulants in Painful Venous Malformations in Children

Pediatric Dermatology, EarlyView.
ABSTRACT Direct oral anticoagulants (DOAC), including dabigatran, apixaban, and rivaroxaban, are increasingly used in adults for painful venous malformations (VMs) instead of subcutaneous drugs such as low molecular weight heparins or fondaparinux. However, these medications are poorly studied in children. In seven children with painful VMs and chronic
Olivia Boccara, Julie Bonigen, Véronique Soupre, Eve Puzenat, Annouk Bisdorff, Ludovic Drouet   +5 more
wiley   +1 more source

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism. [PDF]

Cochrane Database Syst Rev, 2023
Li M, Li J, Wang X, Hui X, Wang Q, Xie S, Yan P, Tian J, Li J, Xie P, Yang K, Yao L.   +11 more
europepmc   +1 more source

In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban [PDF]

, 2007
Grigoris Gerotziafas, Ιsmail Εlalamy, François Depasse, Elisabeth Perzborn, M Samama   +4 more
openalex   +1 more source

Venous Thromboembolism Prophylaxis After TKA: Aspirin, Warfarin, Enoxaparin, or Factor Xa Inhibitors?

Clinical Orthopaedics and Related Research, 2017
Abiram Bala, J. Huddleston, S. Goodman, W. Maloney, D. Amanatullah   +4 more
semanticscholar   +1 more source

Real-world andexanet alfa utilization and the association between delay in administration due to hospital transfer and all-cause inpatient mortality

Research and Practice in Thrombosis and Haemostasis
Background: Evaluations of andexanet alfa for the reversal of factor Xa inhibitor-associated bleeding have been small, with cohorts drawn from single/limited sites.
Huiqiao Fan, Youssef Bessada, Craig I. Coleman   +2 more
doaj  

New anticoagulants for the prevention of venous thromboembolism

Drug Design, Development and Therapy, 2010
Cecilia Becattini, Alessandra Lignani, Giancarlo AgnelliInternal and Cardiovascular Medicine and Stroke Unit, University of Perugia, ItalyAbstract: Anticoagulant drugs have an essential role in the prevention and treatment of thromboembolic diseases ...
Cecilia Becattini, Alessandra Lignani, Giancarlo Agnelli   +2 more
doaj  

Platelet-rich fibrin ensures hemostasis after single-tooth removal under factor Xa inhibitors - a clinical prospective randomized split-mouth study. [PDF]

Clin Oral Investig, 2023
Kyyak S, Jari A, Heimes D, Heider J, Kämmerer PW.   +4 more
europepmc   +1 more source

EXPRESSION OF NOVEL ANTICOAGULANT FUSION PROTEINS INHIBITS FACTOR XA- AND THROMBIN-INDUCED ACTIVATION OF PORCINE VASCULAR ENDOTHELIAL CELLS.

, 2000
Daxin Chen, Kristian Riesbeck, John H. McVey, Geoffrey Kemball‐Cook, Edward G. D. Tuddenham, Robert I. Lechler, Anthony Dorling   +6 more
openalex   +1 more source